Author

C. Reed

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Research Focus:cancer & tumor microenvironment· 2 Organism:bacteria (other)· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

A. Kentsis· 3 shared A. Henssen· 2 shared E. de Stanchina· 2 shared E. Jiang· 2 shared E. Still· 2 shared I. MacArthur· 2 shared R. Koche· 2 shared S. Armstrong· 2 shared

Activity by Year

2017-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Kentsis

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Alternate routes to mnm5s2U synthesis in Gram-positive bacteria

M. Jaroch, G. Sun, H.-C. T. Tsui, C. Reed, J. Sun, M. Joerg, M. E. Winkler, K. C. Rice, T. A. Stich, P. Dedon, P. C. Dos Santos, V. de Crecy-Lagard

This paper identifies a novel pathway for mnm5s2U synthesis in Gram-positive bacteria, revealing alternative biosynthetic mechanisms involving the MnmL enzyme.

bioRxiv · Dec 21, 2023 · PreprintMicrobiology

INO-4800 DNA Vaccine Induces Neutralizing Antibodies and T cell Activity Against Global SARS-CoV-2 Variants

V. M. Andrade, A. Christensen-Quick, J. Agnes, J. Tur, C. Reed, R. Kalia, I. Marrero, D. Elwood, K. Schultheis, M. Purwar, E. Reuschel, T. McMullan, P. Pezzoli, K. Kraynyak, A. Sylvester, , K. E. Broderick

This study evaluates the efficacy of the INO-4800 DNA vaccine against SARS-CoV-2 variants, showing neutralizing antibodies and preserved T cell responses.

bioRxiv · Apr 14, 2021Immunology

Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors

A. Henssen, C. Reed, E. Jiang, H. D. Garcia, J. von Stebut, I. MacArthur, P. Hundsdoerfer, J. Hyun Kim, E. de Stanchina, Y. Kuwahara, H. Hosoi, N. Ganem, F. Dela Cruz, A. Kung, J. Schulte, , A. Kentsis

This study identifies PGBD5 as a therapeutic target in pediatric solid tumors, showing that inhibiting DNA repair pathways with AZD6738 sensitizes these tumors to apoptosis.

bioRxiv · Aug 25, 2017Cancer Biology

Human PGBD5 DNA transposase promotes site-specific oncogenic mutations in rhabdoid tumors

A. Henssen, R. Koche, J. Zhuang, E. Jiang, C. Reed, A. Eisenberg, E. Still, I. MacArthur, E. Rodriguez-Fos, S. Gonzalez, M. Puiggros, A. Blackford, C. Mason, E. De Stanchina, M. Gonen, , A. Kentsis

This study identifies PGBD5 as an oncogenic DNA transposase in rhabdoid tumors, causing site-specific genomic rearrangements through PSS sequences and end-joining repair.

bioRxiv · Feb 23, 2017Cancer Biology

MEF2C phosphorylation is required for chemotherapy resistance in acute myeloid leukemia

F. Brown, E. Still, P. Cifani, S. Takao, C. Reed, S. Ficarro, R. Koche, P. Romanienko, W. Mark, C. O'Donnell, B. Spitzer, C. Stutzke, A. Krivtsov, G. Pouliot, J. Marto, , A. Kentsis

This study identifies MEF2C phosphorylation as a marker of chemotherapy resistance in AML and shows that inhibiting this phosphorylation can overcome resistance in MEF2C-activated cells.

bioRxiv · Feb 9, 2017Cancer Biology